• Widened its regulated markets coverage. Increased product complexity. Increased the proportion of specialty products. 
    • Climbed the filing value chain (Para III to Para IV and Para IV FTFs in the US: 27 Para IV filings as of March 31, 2013).
  • US business: Received approvals for 24 ANDAs
    • Received USFDA approvals for an NDA, Desvenlafaxine base extended-release tablets, a bioequivalent version of the innovator drug Pristiq by Pfizer. They engaged Ranbaxy to market this product in the US. (Why work with a company with such shady dealings?)
  • Leveraged its US filing success to enter the European pharmaceutical market, the second largest in the world.
    • Cemented relationships with large and respected European generic players
  • Extended their therapeutic coverage through the launch of three new divisions in four years (Orthopedic, Ophthalmology, and Dermatology)
    • Launched Dermatology Division in the domestic market with 8 products
    • Launched 25 products as line extensions in existing therapeutic segments
  • Widened their API presence, doubled their product basket to 60 APIs, and increased our specialty products from 5 to 30
  • Invested 110crs and commissioned a new formulations unit, increasing their annual tablet manufacturing capacity to 5 billion.

Targeting a 30-35% growth cagr over the next 2 years: In reality, was only able to achieve 15-16% growth.